When you meet Javier Cuello, founder and CEO of H+Trace, “healthcare innovator” isn’t the first phrase that comes to mind. His journey began not in a lab, but in the concert halls of Argentina.
In 2002, fresh out of engineering school, Cuello built a company recording live shows for artists like Madonna and AC/DC. Music gave him access to the world stage, but not the impact he craved. By 2011, he had taught himself to code, shifting into public service and eventually becoming Director of Science, Technology, and Innovation for Buenos Aires. Government, however, proved too slow.
He turned next to drones, co-founding Argentina’s national chamber for drone companies and piloting a project to transport organs for transplant. That glimpse of how logistics could save lives sparked his defining venture. The turning point came when a close friend was misdiagnosed with diabetes due to mishandled lab samples. Cuello identified a blind spot in diagnostics: the preanalytical phase, responsible for two-thirds of all errors.
In 2021, he launched H+Trace to fix it. Its proprietary Contactless MultiSense platform traces and verifies samples in real time, cutting errors and giving labs full visibility. The system has already tracked more than 11 million samples, supported transplant programs in Argentina, and drawn partnerships with Siemens Healthineers.
Now, Cuello’s team of seven is building Agentic AI for labs, designed to autonomously prioritize urgent samples and optimize workflows. With expansion plans in the U.S., Cuello is betting on a lean, resilient model shaped by years of building under constraints.
“We grew up in a country where you invent your own tools,” he says. “That taught us how to build lean and build well.”
From music studios to transplant labs, Cuello’s path has been anything but traditional. Each reinvention sharpened his ability to spot hidden problems and design practical solutions. With H+Trace, he is not only fixing lab logistics but also building the backbone for more reliable healthcare worldwide.
As the company prepares for U.S. expansion and moves into AI-driven automation, one thing is clear: Cuello is not chasing headlines. He is creating the systems that will determine how quickly, accurately, and safely millions of patients are diagnosed. The stage may have changed, but the mission is larger than ever, transforming precision into trust at the very foundation of medicine.
